Japan Tissue Engineering Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Japan Tissue Engineering's earnings have been declining at an average annual rate of -15.7%, while the Biotechs industry saw earnings growing at 24.8% annually. Revenues have been declining at an average rate of 1.2% per year.
Key information
-15.7%
Earnings growth rate
-15.7%
EPS growth rate
Biotechs Industry Growth | 31.9% |
Revenue growth rate | -1.2% |
Return on equity | -2.7% |
Net Margin | -6.6% |
Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Japan Tissue Engineering makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 2,374 | -157 | 1,032 | 573 |
30 Sep 23 | 2,306 | -319 | 1,103 | 573 |
30 Jun 23 | 2,272 | -448 | 1,163 | 573 |
31 Mar 23 | 2,032 | -729 | 1,221 | 573 |
31 Dec 22 | 1,951 | -782 | 1,218 | 561 |
30 Sep 22 | 2,095 | -651 | 1,213 | 561 |
30 Jun 22 | 2,047 | -636 | 1,194 | 561 |
31 Mar 22 | 2,103 | -497 | 1,123 | 561 |
31 Dec 21 | 2,469 | -396 | 1,274 | 468 |
30 Sep 21 | 2,321 | -461 | 1,192 | 468 |
30 Jun 21 | 2,358 | -421 | 1,149 | 468 |
31 Mar 21 | 2,257 | -466 | 1,084 | 468 |
31 Dec 20 | 2,187 | -335 | 1,068 | 340 |
30 Sep 20 | 2,242 | -288 | 1,044 | 340 |
30 Jun 20 | 2,253 | -277 | 1,018 | 340 |
31 Mar 20 | 2,309 | -287 | 1,013 | 340 |
31 Dec 19 | 2,325 | -210 | 762 | 606 |
30 Sep 19 | 2,317 | -189 | 727 | 606 |
30 Jun 19 | 2,366 | -77 | 698 | 606 |
31 Mar 19 | 2,357 | -333 | 981 | 606 |
31 Dec 18 | 2,199 | -364 | 1,342 | 199 |
30 Sep 18 | 2,204 | -255 | 1,296 | 199 |
30 Jun 18 | 2,188 | -216 | 1,235 | 199 |
31 Mar 18 | 2,271 | 227 | 865 | 199 |
31 Dec 17 | 2,590 | 585 | 936 | 20 |
30 Sep 17 | 2,459 | 507 | 867 | 20 |
30 Jun 17 | 2,282 | 401 | 818 | 20 |
31 Mar 17 | 2,135 | 276 | 824 | 20 |
31 Dec 16 | 1,628 | -165 | 676 | 140 |
30 Sep 16 | 1,500 | -405 | 842 | 140 |
30 Jun 16 | 1,470 | -567 | 974 | 140 |
31 Mar 16 | 1,430 | -681 | 1,051 | 140 |
31 Dec 15 | 1,431 | -651 | 1,013 | 389 |
30 Sep 15 | 1,503 | -600 | 1,007 | 389 |
30 Jun 15 | 1,343 | -713 | 974 | 389 |
31 Mar 15 | 1,321 | -690 | 959 | 389 |
31 Dec 14 | 1,177 | -833 | 858 | 549 |
30 Sep 14 | 1,103 | -861 | 868 | 549 |
30 Jun 14 | 1,083 | -815 | 883 | 549 |
31 Mar 14 | 1,008 | -827 | 864 | 549 |
31 Dec 13 | 847 | -996 | 792 | 462 |
30 Sep 13 | 740 | -1,022 | 735 | 462 |
30 Jun 13 | 692 | -996 | 700 | 462 |
Quality Earnings: 7774 is currently unprofitable.
Growing Profit Margin: 7774 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7774 is unprofitable, and losses have increased over the past 5 years at a rate of 15.7% per year.
Accelerating Growth: Unable to compare 7774's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7774 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.6%).
Return on Equity
High ROE: 7774 has a negative Return on Equity (-2.67%), as it is currently unprofitable.